|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
265.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 7.22 | 6.10 | 5.67 | 5.71 | 9.33 | CEPS(Rs) | 9.16 | 8.49 | 8.68 | 4.26 | 4.99 | DPS(Rs) | 2.00 | 1.75 | 1.50 | 2.75 | 2.75 | Book NAV/Share(Rs) | 48.14 | 42.66 | 38.04 | 64.74 | 65.69 | Tax Rate(%) | 23.78 | 21.88 | 26.24 | 25.32 | 27.89 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 9.78 | 9.67 | 10.25 | 7.31 | 9.30 | EBIT Margin(%) | 9.10 | 8.29 | 9.22 | 6.42 | 10.24 | Pre Tax Margin(%) | 8.96 | 7.97 | 8.75 | 6.03 | 10.06 | PAT Margin (%) | 6.83 | 6.22 | 6.46 | 4.50 | 7.25 | Cash Profit Margin (%) | 8.66 | 8.66 | 9.88 | 6.71 | 7.77 | Performance Ratios | | | | | | ROA(%) | 9.63 | 8.99 | 8.63 | 5.06 | 10.44 | ROE(%) | 15.90 | 15.11 | 16.12 | 8.75 | 14.87 | ROCE(%) | 21.05 | 19.33 | 19.75 | 10.87 | 20.56 | Asset Turnover(x) | 1.41 | 1.44 | 1.34 | 1.12 | 1.44 | Sales/Fixed Asset(x) | 5.31 | 4.97 | 4.55 | 5.20 | 13.71 | Working Capital/Sales(x) | 3.62 | 3.84 | 4.48 | 5.28 | 4.16 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.19 | 0.20 | 0.22 | 0.19 | 0.07 | Receivable days | 105.71 | 90.17 | 77.87 | 89.32 | 82.39 | Inventory Days | 52.54 | 59.98 | 59.23 | 59.91 | 42.34 | Payable days | 125.45 | 117.42 | 125.15 | 130.55 | 83.81 | Valuation Parameters | | | | | | PER(x) | 11.03 | 14.09 | 15.91 | 10.21 | 7.25 | PCE(x) | 8.70 | 10.13 | 10.40 | 13.69 | 13.54 | Price/Book(x) | 1.65 | 2.01 | 2.37 | 1.80 | 2.06 | Yield(%) | 2.51 | 2.04 | 1.66 | 2.36 | 2.03 | EV/Net Sales(x) | 0.74 | 0.86 | 1.03 | 1.09 | 1.03 | EV/Core EBITDA(x) | 6.77 | 7.94 | 8.01 | 12.17 | 9.57 | EV/EBIT(x) | 8.14 | 10.27 | 10.99 | 16.37 | 10.05 | EV/CE(x) | 0.97 | 1.20 | 1.34 | 1.02 | 1.39 | M Cap / Sales | 0.76 | 0.89 | 1.05 | 0.95 | 1.06 | Growth Ratio | | | | | | Net Sales Growth(%) | 8.39 | 12.66 | 40.72 | -4.27 | 34.68 | Core EBITDA Growth(%) | 9.98 | -5.38 | 102.79 | -20.82 | 34.87 | EBIT Growth(%) | 18.46 | 0.30 | 98.80 | -38.14 | 38.26 | PAT Growth(%) | 18.38 | 7.47 | 98.78 | -38.78 | 41.51 | EPS Growth(%) | 18.38 | 7.47 | -0.61 | -38.78 | 41.51 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.00 | 0.01 | 0.07 | 0.27 | 0.03 | Current Ratio(x) | 1.91 | 1.98 | 1.70 | 1.37 | 2.03 | Quick Ratio(x) | 1.46 | 1.37 | 1.12 | 0.99 | 1.46 | Interest Cover(x) | 64.61 | 25.76 | 19.99 | 16.23 | 55.16 | Total Debt/Mcap(x) | 0.00 | 0.01 | 0.03 | 0.15 | 0.01 |
|
|
|
|
|
|